Copy the page URI to the clipboard
Van de Sande, Bram; Lee, Joon Sang; Mutasa-Gottgens, Euphemia; Naughton, Bart; Bacon, Wendi; Manning, Jonathan; Wang, Yong; Pollard, Jack; Mendez, Melissa; Hill, Jon; Kumar, Namit; Cao, Xiaohong; Chen, Xiao; Khaladkar, Mugdha; Wen, Ji; Leach, Andrew and Ferran, Edgardo
(2023).
DOI: https://doi.org/10.1038/s41573-023-00688-4
Abstract
Single-cell technologies, particularly single-cell RNA sequencing (scRNA-seq) methods, together with associated computational tools and the growing availability of public data resources, are transforming drug discovery and development. New opportunities are emerging in target identification owing to improved disease understanding through cell subtyping, and highly multiplexed functional genomics screens incorporating scRNA-seq are enhancing target credentialling and prioritization. ScRNA-seq is also aiding the selection of relevant preclinical disease models and providing new insights into drug mechanisms of action. In clinical development, scRNA-seq can inform decision-making via improved biomarker identification for patient stratification and more precise monitoring of drug response and disease progression. Here, we illustrate how scRNA-seq methods are being applied in key steps in drug discovery and development, and discuss ongoing challenges for their implementation in the pharmaceutical industry.
Viewing alternatives
Metrics
Public Attention
Altmetrics from AltmetricNumber of Citations
Citations from DimensionsItem Actions
Export
About
- Item ORO ID
- 88809
- Item Type
- Journal Item
- ISSN
- 1474-1776
- Academic Unit or School
-
Faculty of Science, Technology, Engineering and Mathematics (STEM) > Life, Health and Chemical Sciences
Faculty of Science, Technology, Engineering and Mathematics (STEM) - Research Group
- Mathematical Biology
- Copyright Holders
- © 2023 Springer Nature Limited
- Related URLs
-
- https://www.ncbi.nlm.nih.gov/pmc/article...(Publication)
- Depositing User
- Wendi Bacon